TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus.
Deucravacitinib
Janus kinase inhibitors
Oral lichen planus
TYK2
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
21
03
2024
received:
08
02
2024
accepted:
30
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
ppublish
Résumé
Erosive oral lichen planus (OLP) is a challenging disease. This T cell driven disorder frequently shows a treatment unresponsive course and strongly limits patients' quality of life. The disease lacks FDA or EMA approved drugs for its treatment and the efficacy of the commonly administered treatments (i.e. topical and systemic steroids, steroid sparing agents) is often only partial. Although the etiopathogenesis of the disease still needs to be fully elucidated, recent advances helped to identify interferon-ɣ (IFN-ɣ) as a pivotal cytokine in OLP pathogenesis, thus making the interference with its signalling a therapeutic target. Janus kinase (JAK) inhibitors therefore gained relevance for their inhibitory effect on IFN-ɣ signalling. While some drugs such as abrocitinib, upadacitinib, tofacitinib directly interfere with IFN-ɣ signalling through blockade of JAK1 and/or JAK2, deucravacitinib, a selective TYK-2 inhibitor indirectly interferes on IFN-ɣ activation through interference with interleukin (IL)-12, a potent promotor for Th1/IFN-ɣ responses. This mechanism of action makes deucravacitinib a candidate drug for the treatment of OLP. Here we provide initial evidence that deucravacitinib 6 mg daily has a beneficial effect in three patients with oral OLP.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15080Informations de copyright
© 2024 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
Références
Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 1968;25(1):31‐42. doi:10.1016/0030-4220(68)90194-1
Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Lichen planus – a clinical guide. J Dtsch Dermatol Ges. 2021;19(6):864‐882. doi:10.1111/ddg.14565
Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2020;34(7):1403‐1414. doi:10.1111/jdv.16464
Didona D, Caposiena Caro RD, Sequeira Santos AM, Solimani F, Hertl M. Therapeutic strategies for oral lichen planus: state of the art and new insights. Front Med (Lausanne). 2022;9:997190. doi:10.3389/fmed.2022.997190
Shao S, Tsoi LC, Sarkar MK, et al. IFN‐gamma enhances cell‐mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561. doi:10.1126/scitranslmed.aav7561
Pietschke K, Holstein J, Meier K, et al. The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21‐A basis for therapeutic JAK1 inhibition. Exp Dermatol. 2021;30(2):262‐270. doi:10.1111/exd.14226
Schmidt T, Solimani F, Pollmann R, et al. T(H)1/T(H)17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol. 2018;142(2):669‐672 e7. doi:10.1016/j.jaci.2018.02.044
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020;145(6):1708‐1710e2. doi:10.1016/j.jaci.2020.01.031
Balestri R, Bortolotti R, Rech G, Girardelli CR, Zorzi MG, Magnano M. Treatment of oral erosive lichen planus with upadacitinib. JAMA Dermatol. 2022;158(4):457‐458. doi:10.1001/jamadermatol.2022.0147
Moussa A, Colla T, Morrison B, Sinclair R. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib. Australas J Dermatol. 2022;63(2):276‐277. doi:10.1111/ajd.13811
Solimani F, Mesas‐Fernandez A, Dilling A, et al. The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus. J Eur Acad Dermatol Venereol. 2023;37. doi:10.1111/jdv.19069. Epub ahead of print.
Trinchieri G. Interleukin‐12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133‐146. doi:10.1038/nri1001
Ormond M, McParland H, Thakrar P, et al. Validation of an oral disease severity score for use in oral lichen planus. Br J Dermatol. 2022;186(6):1045‐1047. doi:10.1111/bjd.20968
Weinberg MA, Hassan H. Bleeding on probing: what does it mean? Gen Dent. 2012;60(4):271‐276.
Arya R, Sharma RK, Tanwar N, Gupta A. Assessment of periodontal status in patients with oral lichen planus. Quintessence Int. 2024;55(1):4‐16. doi:10.3290/j.qi.b4343127
Sanadi RM, Khandekar PD, Chaudhari SR, Javali MA, Gurav NU. Association of periodontal disease with oral lichen planus: a systematic review and meta‐analysis. J Oral Maxillofac Pathol. 2023;27(1):173‐180. doi:10.4103/jomfp.jomfp_178_22
Ghoreschi K, Augustin M, Baraliakos X, et al. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J Dtsch Dermatol Ges. 2021;19(10):1409‐1420. doi:10.1111/ddg.14585
Ross SH, Cantrell DA. Signaling and function of interleukin‐2 in T lymphocytes. Annu Rev Immunol. 2018;36:411‐433. doi:10.1146/annurev-immunol-042617-053352
Reem GH, Yeh NH. Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science. 1984;225(4660):429‐430. doi:10.1126/science.6429853
Shen Z, Gao X, Ma L, Zhou Z, Shen X, Liu W. Expression of Foxp3 and interleukin‐17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants. Arch Dermatol Res. 2014;306(5):441‐446. doi:10.1007/s00403-013-1429-3
Pouralibaba F, Babaloo Z, Pakdel F, Aghazadeh M. Serum level of interleukin 17 in patients with erosive and non‐erosive oral lichen planus. J Dent Res Dent Clin Dent Prospects. 2013;7(2):91‐94. doi:10.5681/joddd.2013.016
Husein‐ElAhmed H, Steinhoff M. Potential role of interleukin‐17 in the pathogenesis of oral lichen planus: a systematic review with meta‐analysis. J Eur Acad Dermatol Venereol. 2022;36(10):1735‐1744. doi:10.1111/jdv.18219
Ismail FF, Sinclair R. Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin‐23/interleukin‐17 pathway in the pathogenesis of lichen planus. Australas J Dermatol. 2020;61(2):e244‐e245. doi:10.1111/ajd.13183
Solimani F, Pollmann R, Schmidt T, et al. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol. 2019;10:1808. doi:10.3389/fimmu.2019.01808
Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52‐week, randomized, double‐blinded, placebo‐controlled phase 3 POETYK PSO‐1 trial. J Am Acad Dermatol. 2023;88(1):29‐39. doi:10.1016/j.jaad.2022.07.002
Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52‐week, randomized, double‐blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40‐51. doi:10.1016/j.jaad.2022.08.061